anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: microbiology, biotechnology. SUBSTANCE: vaccine is introduced, in equal portions by volume, with dead pasteurella of standardized fist-generation microbial cell both in capsular and capsule-free variants after isolation out of poultry body. For this purpose, a susceptible organism should be infected orally with a control-industrial pasteurella strain obtained by the method of pasteurella virulence increase, and at the moment of lethality one should wash maternal capsule- free bacteria in heated buffered physiological solution of sodium chloride (pH 7.0; 35-40 C), immediately after cooling off and postmortem rigidity at environmental temperature being 15-25 C (optimum 20 C) (in 3-4 h after death depending upon body weight of affected poultry) - maternal capsular bacteria which are separately inoculated, correspondingly, upon Hottinger's broth heated up to 37-38 C (pH 7.2-7.4) to be cultivated upon nutritive medium identical both by quality and temperature. At 9-10-h age of every pasteurella culture one should pour off, correspondingly, per a half of their volume into sterile vials and cool gradually for 2-3 h at environmental temperature being 15-25 C (optimum 20 C) till complete encapsulation of microbial cells at the state of rest. Then it is necessary to simultaneously introduce formalin at final concentration being 0.3% into cooled halves of encapsulated cultures and continuously cultivated halves of capsule-free pasteurella cultures. Concentrated biomass of capsular and capsule-free pasteurella, correspondingly, should be combined at equal portions by volume to prepare working suspension of vaccine antigen in buffered physiological solution of sodium chloride at 0.3%-formalin concentration at 30 bln mc/ml. Working antigenic suspension should be mixed with known oily adjuvant at equal ratio by volume to be used as the vaccine. The latter is safe being immunogenic and economically harmless. EFFECT: higher efficiency of prophylaxis. 2 cl, 7 ex, 4 tbl
PURPOSE:A granular animal drug, obtained by crystallizing an animal drug by the action of a nucleating agent, and coating the resultant crystallized animal drug with a waxy material which is solid at ordinary temperature, and useful for oral administration by mixing in a feed, etc. CONSTITUTION:An animal drub pharmaceutical obtained by coating an animal drug, e.g. antibiotic, sulfamide drug, particularly slightly crystallizing thiolane based compound having 30-100 deg.C melting point, with a hydrophobic waxy material, e.g. higher fatty acid. In the process, a fine powdery nucleating agent, e.g. inorganic powder such as mica, talc, kaolin, or titanium oxide, or organic powder such as lactose or dextrin, insoluble in the waxy material in an amount of 0.01pts.wt. or more, more preferably 0.05pts.wt. or more based on 100pts.wt. animal drug is incorporated with the hydrophobic waxy material to facilitate the crystallization of the animal drug in the waxy material. The above- mentioned pharmaceutical may be coated with a suitable polymer, e.g. gelatin or methyl cellulose, as desired.
PURPOSE:To obtain the surface curing-accelerating agent for prosthetic materials, capable of surely curing the surfaces of the dental prosthesis resin materials which each may contain a filler, reducing the amounts of non- polymerized radically polymerizable monomers, improving the mechanical strength, and reducing the irritability. CONSTITUTION:A water-soluble surface curing-accelerating agent contains a reducing compound in an amount of 0.1-80wt.%. 0.5-10wt.% of an organic amine, 1-40wt.% of an organic phosphine or its salt, 0.5-30wt.% of an organic sulfonic acid thiol ester or 1-50wt.% of an inorganic sulfur compound is preferably used as the reducing compound. The surface curing-accelerating agent may further contain 5-50wt.% of an aqueous thickening agent and 150wt.% of a water-miscible dilution solvent. A curable composition (prosthetic material) comprising a radically polymerizable monomer, a polymerization initiator and, if necessary, a filler is radically polymerized at approximately the ordinary temperature, and subsequently curing-molded. The prepared prosthetic material is brought into contact with the surface curing-accelerating agent at 4-90 deg.C.
<P>PROBLEM TO BE SOLVED: To provide a user-friendly electronic medical chart automatic scroll system which easily displays medical examination information.  <P>SOLUTION: Patient name information and each the medical examination information are stored. Display editing information and scroll speed information are set and stored. The stored patient name information is selected (step 30). Each the medical examination information corresponding to the selected patient name information is edited on the basis of the display editing information. Each of the edited medical examination information pieces is stored together with the corresponding patient name information as editing information (step 34). The stored editing information is displayed on a monitor. The editing information is scrolled and displayed on the basis of the scroll speed information (step 36). A control method for a scroll direction or a scroll stop is selected by a click of a mouse to control a scroll state of the editing information.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A method and system for determining a comfort score to evaluate an interface to be worn on a face of a user of a respiratory therapy device. Facial features of the user are determined based on a facial image. Facial feature data from a user population and a corresponding set of interface dimensional data from interfaces used by the user population is stored. Operational data of respiratory therapy devices used by the user population with the interfaces is stored. A comfort score for the interface is determined via an evaluation tool. The evaluation tool determines the comfort score based on the facial features of the user, the output of a simulator simulating the interface on the plurality of facial feature data, and the operational data. The comfort score is displayed on a display to assist a user in selection of an interface with the best comfort.
In aging societies, social and economic burdens of aging-related diseases are increasing significantly. Senotherapy, which targets aging by eliminating senescent cells (senolytics) or removing sources of chronic inflammation (senostatics), are proposed as novel strategies for aging-related diseases. Aged or frail people suffer a decline of tissue reserve capacity during aging. Resilience, which is much reduced in older people, is essential for recovery from diseases, stresses or crises. Impaired resilience is one of the reasons why aged people experience a gradual waning of their daily activity and an increase of multimorbidity. Calorie restriction results in senostatic alleviation of chronic inflammation, whereas senolytic drugs induce apoptosis of senescent cells, which exacerbate aging by excreting inflammatory factors. Thus, both senolytics and senostatics are expected to reduce sterile inflammation, originating from senescent cells. Geriatr Gerontol Int 2024; 24: 845-849.
Processes are described for obtaining highly purified tetrahydrocannabinolic acid (THCa) from cannabis. Solvent extraction is performed on plant material or extract, followed by removal of impurities using sequential liquid–liquid extractions to purify cannabinoid carboxylic acids therefrom based on chemical properties of carboxylate salts. The product liquor, comprising THCa in solvent, is largely free of impurities, and high in THCa. Further steps can be conducted to obtain a highly enriched solution using chromatography and subsequent crystallization of THCa in 99% purity. THCa can be used as starting material for other products that include THC by decarboxylation. Optionally, triglyceride extraction of a washed aqueous phase can be used to prepare a THCa composition without chromatographic purification. A pre-processing aqueous extraction with pH manipulations may be used to remove biomass prior to solvent extraction, while maintaining THCa and optionally other cannabinoid acids.
BACKGROUND: Right ventricular dysfunction (RVD) complicates 30%-40% of cases in acute myocardial infarction (AMI) and cardiogenic shock (CS). There are sparse data on the effects of RVD on outcomes and the impact of providing early left ventricular (LV) mechanical circulatory support (MCS) on RV function and hemodynamics.
METHODS AND RESULTS: Between July 2016 and December 2020, 80 sites participated in the study. All centers agreed to treat patients with AMI-CS using a standard protocol emphasizing invasive hemodynamic monitoring and rapid initiation of LV-MCS. RVD was defined as a right atrial (RA) pressure of >12 mm Hg and a pulmonary artery pulsatility index (PAPI) of <1 within 24 hours of the index procedure. The primary outcome was survival to discharge. In a subgroup analysis, data available from the Automated Impella Controller console was used to analyze diastolic suction alarms from LV placement signal and its relation to RVD. A total of 361 patients were included in the analysis, of whom 28% had RVD. The median age was 64 years (interquartile range 55-72 years), 22.7% were female and 75.7% were White. There was no difference in age, sex, or comorbidities between those with or without RVD. Patients with RVD had a higher probability of active CPR during LV-MCS implant (14.7% vs 6.3%), Society for Cardiovascular Angiography and Interventions stage E shock (39.2% vs 23.2%), and higher admission lactate levels (5.1 mg/dL vs 3.0 mg/dL). Survival to discharge was significantly lower among those with RVD (61.8% vs 73.4%, odds ratio 0.89, 95% confidence interval 0.36-0.95, P = .031). This association remained significant in the multivariate analysis. There was no significant difference in hemodynamic variables within 24 hours of LV-MCS support among those with or without RVD. At 24 hours, patients with a CPO of >0.6 W and a PAPi of >1 had a trend toward better survival to discharge compared with those with a CPO of ≤0.6 W and a PAPi of ≤1 (77.1% vs 54.6%, P = .092). Patients with RVD were significantly more likely to have diastolic suction alarms within 24 hours of LV-MCS initiation.
CONCLUSIONS: RVD in AMI-CS is common and associated with worse survival to discharge. Early LV-MCS decreases filling pressures rapidly within the first 24 hours and decreases the rate of RVD. Achieving a CPO of >0.6 W and a PAPi of >1 within 24 hours is associated with high survival. Diastolic suction alarms may have usefulness as an early marker of RVD.
Participants will receive four preoperative doses of PDL-1 inhibitor Serplulimab in adults with untreated, surgically resectable early (stage IB, II, or IIIA) NSCLC. Serplulimab (at a dose of 4.5mg per kilogram of body weight) was administered intravenously every 3 weeks, with surgery planned approximately 4 weeks after the last dose.
FIELD: medicine, gynecology. SUBSTANCE: it is suggested to apply ozone-oxygen mixture at 17-18 ml/g ozone concentration as rectal insufflations. One should begin with injecting 60-80 ml followed by gradual increase of mixture volume by 20-30 ml to reach 160 ml to the final procedure. Therapy course consists of 5-7 procedures conducted every other day. The present innovation decreases the risk of local and general complications. EFFECT: higher efficiency of therapy. 3 ex
Active Prewarming will be performed during 30 minutes, using a forced-air blanket over the whole body and connected to a forced-air warmer set up at 43 degrees centigrade. Patients will be actively warmed during the intraoperative period.
Chronic kidney disease\[CKD\] is becoming a serious health problem.The number of people with impaired renal function is rapidly rising, especially in industrialized countries. It is increasing rapidly worldwide at an annual growth rate of 8%. Chronic kidney disease \[CKD\] is defined as kidney disease that has been present for months to years. Chronic kidney disease \[CKD\] is a complex disease impacting more than twenty million individuals. Progression of CKD is associated with a number of serious complications, including increased incidence of cardiovascular disease, hyperlipidemia, anemia and metabolic bone disease .CKD patients should be assessed for the presence of these complications and receive optimal treatment to reduce their morbidity and mortality .

CKD affects thyroid function in many ways, including low thyroid circulating hormone levels, altered peripheral hormone metabolism, insufficient binding to carrier proteins, reduced tissue thyroid hormone content and altered iodine storage in the thyroid gland.Thus,inCKD,thyroid hormone metabolism is impaired. . Hypothyroidism in patients with renal failure causes many metabolic and clinical problems, and both these diseases can mutually exacerbate their disturbances.. Chronic kidney disease has been known to affect thyroid hormones metabolism .Low serum level of T3 and T4 are most remarkable laboratorial finding. A high incidence of goiter and nodules on thyroid ultrasonography has been reported in patients with end stage renal failure\[ESRF\]. CKD is often associated with dyslipidemia. Several factors contribute to these changes. Patient with CKD have a reduction in the activity of lipoprotein lipase and hepatic triglyceride lipase. This interferes with uptake of triglyceride rich Apo lipoprotein B containing lipoprotein by the liver and in peripheral tissue, yielding increased circulation of these atherogenic lipoproteins. Early diagnosis of thyroid and lipid disorders by regular screening, and treatment of such disorders in CKD patients may be highly beneficial to slow progression of CKD.
The aim of this randomized controlled parallel group single-center study is to determine the effect of progressive muscle relaxation exercise on mental health and quality of life in university students. The research was conducted online with Tokat Gaziosmanpaşa University Reşadiye Vocational School Health Care Services Department Aged Care Program 1st and 2nd grade students. The research was carried out with a total of 86 students, 43 of which were in the intervention group and 43 in the control group. The data of the study were collected using the Introductory Information Form, Brief Symptom Inventory, SF-36, Progressive Muscle Relaxation Exercise Follow-up Form. University students in the intervention group were given progressive muscle relaxation exercise at least 4 times a week for 6 weeks. No intervention was made in the control group. University students in the control group were asked to continue their daily lives. Ethics committee permission, institutional permission, scale usage permission and written consent of the participants were obtained for the research.
Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect.

An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.
Iron supplementation of 4mg/kg/day will start when infant is on full enteral feedings of 120-150mL/kg/day and at least two weeks old. Iron dosing will be adjusted for weight at weekly intervals to maintain dosing at 4mg/kg/day.
Research has shown that bupropion is a safe and effective treatment for both ADHD and nicotine dependence in individuals without SUD, and newer research provides empirical support for its unique pharmacotherapeutic properties and potential for treating other addictive disorders (e.g., methamphetamine dependence, pathological gambling). No controlled studies have yet evaluated bupropion's safety and efficacy for ADHD and SUD (including nicotine and cannabis) in adolescents. The lack of research on the safety and efficacy of medications in adolescents with SUD and psychiatric comorbidities contributes to a serious lack of integrated treatment for commonly co-occurring mental health and substance problems in community-based adolescent drug treatment programs. This then contributes to poorer treatment outcomes and prognosis for the large number of comorbid youths with substance abuse and mental health problems that significantly impact public health. The specific aims of the proposed study will address this research gap by conducting a 16-week randomized controlled trial of bupropion vs. placebo to evaluate the safety and efficacy of this low abuse potential medication on ADHD, nicotine dependence, and cannabis use disorders (not excluding other SUD) in 130 adolescents (13-19) receiving concurrent outpatient substance treatment (CBT). The study design and analytic approach will enable assessment of the complex inter-relationship between change in ADHD, depression/dysphoria (and other psychiatric symptoms) and change in nicotine, cannabis and other substance use within and between treatment groups. Thus, the study addresses important research gaps in at least two priority areas of the National Institute on Drug Abuse/ National Institutes of Health(NIDA/NIH) research agenda: 1) research on effective treatments for adolescents with addiction and psychiatric comorbidity, and 2) medications development research for nicotine and cannabis use disorders in adolescents.
1. The medicine capsule for administering medicines by inhalation, it is characterised in that it is constituted by a skeleton with isometric form in all three dimensions, with the diameter of 2-4 μm, consisting of primary particles with the size of 10-50 nm, connected by the forces of adhesion or by sintering. It is characterised by porosity above 60 percent. It is made of a material tolerated toxicologically by the human organism, preferably of titanium oxide, and saturated with a medicine in liquid form. 2. The method of producing a medicine capsule for administering medicines by inhalation, characterised in that the precursor of the solid phase, preferably titanium tetrachloride in the form of vapour, is introduced into a flame reactor. The produced solid particles - with the original size of 10-50 nm - of a material, tolerated toxicologically by the human organism, in the form of agglomerates with the diameter of 2-4 μm, is collected on the substrate cooled down to the temperature of about 25 degrees Celsius, located over the flame. The size of agglomerates is controlled through the control of the reaction temperature and of the time spent by the reacting substances in the flame zone. The produced agglomerates are saturated with the medicine to be inhaled.
Omega-3 (ω3) fatty acids are widely investigated for their anti-inflammatory potential, however, there is little evidence regarding their action in the lung parenchyma in the context of obesity. The objective is to investigate the effects of flaxseed oil (FS), rich in α-linolenic (C18:3 - ω3), on the lungs of obese mice. Mice were fed a high-fat diet (HF) for 8 weeks to induce obesity. Subsequently, a part of these animals received HF containing FS oil for another 8 weeks. The HF consumption induced weight gain and hyperglycemia. The lung parenchyma shows a complete fatty acids profile, compared to the control group (CT). In the lung parenchyma, FS increases the ω3 content and, notwithstanding a reduction in the interleukins (IL) IL1β and IL18 contents compared to HF. However, FS promoted increased alveolar spaces, followed by MCP1 (Monocytes Chemoattractant Protein-1) positive cell infiltration and a dramatic reduction in the anti-inflammatory cytokine, IL10. Despite reducing the pulmonary inflammatory response, the consumption of a food source of ω3 was associated with alterations in the lipid profile and histoarchitecture of the lung parenchyma, which can lead to the development of pulmonary complications. This study brings an alert against the indiscriminate use of ω3 supplements, warranting caution.
DB phase: TDF 300 mg + TAF placebo for up to 50 weeks. OLE phase: TAF 25 mg for up to 52 weeks.
Exendin(9-39) infusion. GLP-1 receptor antagonist used as a study tool on experimental days.
INTRODUCTION: Women vaccinated through the initial catch-up HPV vaccination programme (2011/12 to 2013/14) first became eligible for cervical screening in 2019 at age 25. This study aims to examine the changes in detection of HG cytology outcomes in 25-year-olds screened from 2010 to 2022 compared to population data on HPV vaccination in this group.
METHODS: This was an ecological-type study. Cytology results from the CervicalCheck database from 2010 to 2022 (High Grade, Low Grade, and No Abnormality Detected) were plotted against data from the National Immunisation Office on the uptake of HPV vaccinations in females from 2010 to 2022.
RESULTS: Vaccination rates in the catch-up programme were lower (44-70%) than for routine HPV immunisation at age 12/13 in 2010/11 (81%). The rate of high-grade cytology in 25-year-olds in 2015-2018 was 3.7% of all cytology tests taken in this age group. For the corresponding period from 2019 to 2022 (when vaccinated women were attending screening), the average percentage of HG cytology in 25-year-olds was 1.5%, representing a significant reduction in HG cytology proportions (p < 0.001).
CONCLUSION: This study provides early evidence of the potential impact of HPV vaccination on cervical disease in the Republic of Ireland. Despite lower vaccination uptake in the initial catch-up group, we are seeing early signs of the positive protective effect of HPV vaccination in women at the time of their first cervical screening test. Plans to incorporate individual-level HPV vaccination status for women on the cervical screening register will allow more detailed assessment of the impact of HPV vaccination.
Patients assigned to this group are treated with dual therapy with vonoprazan 20 mg bid and amoxicillin 500 mg tid for 1 week. The eradication rate attained with this regimen is measured.
BACKGROUND: Heart disease and strokes are leading global killers. While atrial arrhythmias are not deadly by themselves, they can disrupt blood flow in the heart, causing blood clots. These clots can travel to the brain, causing strokes, or to the coronary arteries, causing heart attacks. Additionally, prolonged periods of elevated heart rates can lead to structural and functional changes in the heart, ultimately leading to heart failure if untreated. The left atrium, with its more complex topology, is the primary site for complex arrhythmias. Much remains unknown about the causes of these arrhythmias, and computer modeling is employed to study them.
METHODS: We use N-body modeling techniques and parallel computing to build an interactive model of the left atrium. Through user input, individual muscle attributes can be adjusted, and ectopic events can be placed to induce arrhythmias in the model. Users can test ablation scenarios to determine the most effective way to eliminate these arrhythmias.
RESULTS: We set up muscle conditions that either spontaneously generate common arrhythmias or, with a properly timed and located ectopic event, induce an arrhythmia. These arrhythmias were successfully eliminated with simulated ablation.
CONCLUSIONS: We believe the model could be useful to doctors, researchers, and medical students studying left atrial arrhythmias.